Signs and symptoms of ocular surface status in glaucoma patients switched from timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: a 6-month efficacy and tolerability, multicenter, open-label prospective study

Gemma Caterina Maria Rossi University Eye Clinic of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy +39 0382 526213; +39 0382 527006; [email protected]

Carmine Tinelli Biometry and Epidemiology Service, IRCCS Policlinico San Matteo Foundation, Pavia, Italy

Gian Maria Pasinetti UO Oculistica, Istituto Beato Palazzolo, Bergamo, Italy

Marina Fusetti Private practice, Pavia, Italy

Claudio Pallavicini Private practice, Pavia, Italy

Massimo Stringa Private Practice, Voghera, Italy

Sauro Vacchi Private Practice, Voghera, Italy

Francesco Stringa University Eye Clinic of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy +39 0382 526213; +39 0382 527006; [email protected]

Paolo Emilio Bianchi University Eye Clinic of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy +39 0382 526213; +39 0382 527006; [email protected]

show all

Signs and symptoms of ocular surface status in glaucoma patients switched from timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: a 6-month efficacy and tolerability, multicenter, open-label prospective study

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Signs and symptoms of ocular surface status in glaucoma patients switched from timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: a 6-month efficacy and tolerability, multicenter, open-label prospective study

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date